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Abstract Glycans serve as important regulators of antibody
activities and half-lives. IgE is the most heavily glycosylated
antibody, but in comparison to other antibodies little is known
about its glycan structure function relationships. We therefore
describe the site specific IgE glycosylation from a patient with a
novel hyper IgE syndrome linked to mutations in PGM3,
which is an enzyme involved in synthesizing UDP-GlcNAc,
a sugar donor widely required for glycosylation. A two-step
method was developed to prepare two IgE samples from less
than 1 mL of serum collected from a patient with PGM3 mu-
tation and a patient with atopic dermatitis as a control subject.
Then, a glycoproteomic strategy was used to study the site-
specific glycosylation. No glycosylation was found at
Asn264, whilst high mannose glycans were only detected at
Asn275, tri-antennary glycans were exclusively observed at
Asn99 and Asn252, and non-fucosylated complex glycans
were detected at Asn99. The results showed similar glycosyla-
tion profiles between the two IgE samples. These observations,
together with previous knowledge of IgE glycosylation, imply
that IgE glycosylation is similarly regulated among healthy
control, allergy and PGM3 related hyper IgE syndrome.
Keywords IgE . Glycoproteomics . Hyper IgE Syndrome .
Phosphoglucomutase 3
Introduction
All antibodies are glycosylated and the glycans serve as impor-
tant regulators for antibody activities [1–6] and half-lives [7, 8].
IgE is known to play a key role in allergic responses [9]. It is the
most heavily glycosylated antibody and contains seven poten-
tial N-glycosylation sites at Asn21, 49, 99, 146, 252, 264 and
275 in the heavy chain constant region. However, glycosylation
of IgE is not extensively studied, due to its low concentration in
the blood, making it difficult to prepare. In the 1970s, mono-
saccharide ratios of glycans at each potential glycosylation site
on a myeloma IgE were reported [10–12]. High variations of
glycosylation among different sites were observed, for example
Asn264 was found not to be glycosylated and only Man and
GlcNAc residues were detected at Asn275. The other 5 sites
were occupied by complex glycans with different levels of
fucosylation and sialylation. In 2004, an overall profile of IgE
N-glycans from an atopic patient was obtained using HPLC
[13], which detected 24 N-glycans including both high man-
nose glycans and complex glycans. More than 75 % of the
glycan pool was sialylated, almost 60 % of glycans were core
fucosylated, and 13 % of glycans had bisecting GlcNAc.
Recently, a mass spectrometry based glycoproteomic strategy
was used to obtain a site specific analysis of IgE N-
glycosylation [14]. The results showed for the first time the
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glycan structures at each site on IgE, which was collected from
a hyperimmune donor, from the pooled serum of multiple
nondiseased donors, and from the pooled serum of 2 patients
with IgEmyeloma. Consistent with themonosaccharide studies
of a myeloma IgE, the data showed Asn264 was not glycosyl-
ated and Asn275 was glycosylated exclusively with high man-
nose glycans.
However, little is known about the glycosylation of IgE
from patients with hyper IgE syndrome (HIES). HIES is a
primary immunodeficiency disorder which is characterized
by dramatically elevated IgE levels, accompanied by other
symptoms such as eczema, recurrent staphylococcal skin in-
fections and pulmonary infections [15]. The disease was first
reported in 1966 [16], and its autosomal dominant inheritance
pattern was discovered in 1999 [17]. Mutations in two pro-
teins were discovered to be linked to the disease: signal trans-
ducer and activator of transcription 3 (STAT3) [18, 19] and
dedicator of cytokinesis protein 8 (DOCK8) [20, 21].
Recently, a novel hyper IgE syndrome has been discovered
[22, 23], without mutations in STAT3 or DOCK8. Instead, the
disease is linked to mutations in phosphoglucomutase 3
(PGM3). Unlike other phosphoglucomutases, which catalyse
the conversion of Glc-6-phosphate and Glc-1-phosphate,
PGM3 catalyses the conversion of GlcNAc-6-phosphate and
GlcNAc-1-phosphate, producing the precursor for synthesiz-
ing UDP-GlcNAc, which is a sugar donor required for glyco-
sylation. Our glycomic studies have already found dramatic
changes of N-glycans in Epstein–Barr virus (EBV) treated B
cells and neutrophils from these patients [23]. Moreover, our
glycomic studies of IgE showed that the overall profile of N-
glycans did not change significantly from a patient with
PGM3 mutations and a patient with atopic dermatitis [23].
Both IgE samples had high mannose glycans and complex
glycans. Most of the complex glycans were bi-antennary with
core fucose and sialic acid. BisectingGlcNAcwas observed in
some of the bi-antennary structures. Tri-antennary glycans
and truncated glycans were also detected. The relative inten-
sities among these glycans were similar between the two IgE
samples. However, it is unknown whether there are site spe-
cific changes which could be involved in the elevated IgE
which could affect IgE activities and half-life.
In this study, immunoprecipitation was used to prepare two
IgE samples from less than 1mL of sera/plasma: one was from
a patient with PGM3 mutation, the other was from a patient
with atopic dermatitis as a control subject. Then we used
glycoproteomic strategies to study the glycans at each poten-
tial glycosylation site of the two samples. The results showed
there are no significant differences between the two IgE sam-
ples. Moreover, our data combined with a recent study [14]
show that IgE glycoproteomic spectra are similar among
healthy controls, patients with allergy and the patient with
HIES caused by PGM3 mutation. These observations imply
that, despite alterations occurring in the N-glycome of
immune cells from patients with PGM3mutations, the elevat-
ed IgE in allergy and HIESmay not be related to glycosylation
on the antibody itself.
Materials and methods
Serum/plasma samples
Serum/plasma samples were collected from the Centre of
Chronic Immunodeficiency (CCI), University Medical
Center Freiburg, under human subject protocols approved by
local ethics committees at University College London, the
University of Freiburg and the Pasteur Institute of Tunis.
IgE enrichment
IgE was enriched by immunoprecipitation using Pierce®
Direct IP Kit (Thermo Scientific, Basingstoke, UK) according
to the manufacturer’s instructions with some modifications. In
order to immobilise an anti-IgE antibody on beads, the Pierce
Spin Column was loaded with 30 μL AminoLink Plus
Coupling resin and the liquid was removed by centrifuging
at 1000 g for 1 min. Then, 300 μL 1× Coupling Buffer was
used to wash the resin twice. After that, 185 μL H2O, 15 μL
20× Coupling Buffer, 100 μL IgE (4F4): sc-51994, mouse
monoclonal antibody raised against IgE of human origin
(Santa Cruz Biotechnology, Heidelberg, Germany) and
4.5 μL sodium cyanoborohydride were added onto the resin
in the column and incubated at room temperature for 90min in
a rotator. The liquid was removed from the spin column by
centrifuging at 1000 g for 1 min. The resin was washed twice
with 300 μL 1× Coupling Buffer and 300 μL of 1×
Quenching Buffer. Then, 300 μL of 1× Quenching Buffer
and 4.5 μL of sodium cyanoborohydride were added and in-
cubated at room temperature for 15 min on a rotator. The
liquid was removed from the column again by centrifuging.
Finally, the resin was washed once with 300 μL of 1×
Coupling Buffer and 6 times with 200 μL washing solution.
When the immobilization was completed, the resin was mixed
with 600 μL of serum/plasma and gently rotated at 4 °C over-
night. After that, 75 μL elution buffer was added to the resin
and incubated for 10 min at room temperature. IgE was col-
lected by centrifuging at 1000 g for 1 min.
SDS-PAGE
The eluate was lyophilized and analysed by Novex®
NuPAGE® SDS-PAGE Gel System (Invitrogen Ltd, Paisley,
UK). Samples were dissolved in NuPAGE® LDS Sample
Buffer, incubated at 70 °C for 10 min, loaded to Novex®
NuPAGE® 3–8 % Tris-Acetate Mini Gels, and run at 150 V
constant in Tris-Acetate SDS Running buffer. Gels were
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stained using Novex® Colloidal Blue Staining Kit. Gel bands
of interest were chopped into 1×1 mm pieces, which were
destained at room temperature using 50 mM ammonium hy-
drogen carbonate (Sigma-Aldrich, Poole, UK), pH 8.4 for
5 min, and mixed with equal amount of acetonitrile (Romil,
Cambridge, UK) for another 5 min. The supernatant was
discarded. The gel pieces were completely destained by repeat-
ing the two steps several times and were dried on a Thermo
Savant SPD121P Speed Vac (Thermo Scientific, Basingstoke,
UK). The samples in the gel pieces were reduced using 10 mM
dithiothreitol (Roche Applied Science, East Sussex, UK) in
ammonium hydrogen carbonate, pH 8.4 at 56 °C for 30 min.
The dithiothreitol was then removed and the gel was washed
and shrunk using 200 μL acetonitrile, and dried in the Speed
Vac. Reduced samples were carboxymethylated by adding
200 μL 55 mM iodoacetic acid (Sigma-Aldrich, Poole, UK)
in 50 mM ammonium hydrogen carbonate pH 8.4, and incu-
bating in the dark for 30 min. After that, the iodoacetic acid
solution was removed. The gel pieces were shrunk using
200 μL acetonitrile, and dried in the Speed Vac.
In-gel digestion and (glyco)peptides extraction
The samples in the gel pieces were digested by trypsin
(Promega, Hampshire, UK) or chymotrypsin (Promega,
Hampshire, UK) into (glyco)peptides. Different proteolytic
enzymes were utilized to facilitate analysis of individual gly-
cosylation sites in glycopeptides. For trypsin digestion, 1/50
(w/w) of trypsin in 50 mM ammonium hydrogen carbonate,
pH 8.4 was added to the dried gel pieces and incubated for
37 °C overnight. For chymotrypsin digestion 1/20 (w/w) of
chymotrypsin in 50 mM ammonium hydrogen carbonate,
pH 7.8 was added and incubated at 37 °C overnight. After
the digestion, the supernatant was transferred to a new tube.
Then 50 μL of 0.1 % (v/v) trifluoroacetic acid (Romil,
Cambridge, UK) was added to the gel pieces and incubated
at 37 °C for 10 min, followed by 100 μL acetonitrile and
incubated at 37 °C for 15 min. The supernatant was pooled
with the previous supernatant. This step was repeated twice.
The combined supernatant was reduced to 10 μL in a Speed
Vac for mass spectrometric analysis.
Mass spectrometric analysis
MALDI-TOF/TOF was used for protein identification of the gel
bands. The (glyco)peptides were mixed with α-CHCA (Sigma-
Aldrich, Poole, UK) matrix (10 mg/mL in 50 % acetonitrile,
0.05 % trifluoroacetic acid), spotted on a MALDI plate, dried,
and analysed using a 4800 MALDI-TOF/TOF™ Analyzer
(Applied Biosystems, Darmstadt, Germany). The data were
analysed using GPS Explorer™ Software (Applied
Biosystems, Darmstadt, Germany). Both MS and MS/MS data
were used to search 283,454 entries in release 54.2 of the
SwissProt database with version 2.2 of the Mascot database
search algorithm (www.matrixscience.com) with the following
parameters: peptide masses were fixed as monoisotopic, partial
oxidation of methionine residues was considered, partial
carboxymethylation of cysteine residues was considered, the
mass tolerance was set at 75 ppm for precursor ions and 0.1 Da
for fragment ions and tryptic digests were assumed to have no
more than one missed cleavage. Peptide matches from both MS
and MS/MS data were used to generate probability-based
Mowse protein scores. Scores of >55were considered significant
(P<0.05). Glycoproteomic analysis was carried out according to
a previous report [24], The (glyco) peptides were separated on a
Pepmap C18 nanocapillary column (15 cm length, 75 mm inter-
nal diameter) fitted to a nano-HPLC system (LC Packings) con-
nected to an ABI QSTAR Pulsar Hybrid LC/MS/MS system
(Applied Biosystems/MDS Sciex). A gradient from 0.05 % (v/
v) formic acid in 95.5 % (v/v) water/acetonitrile to 0.05 % (v/v)
formic acid in 95.5 % (v/v) acetonitrile/water solution were
employed. Data were analysed using Analyst QS Software.
Results
Preparation and proteomic identification of IgE
IgE from a patient with PGM3 mutation and a patient
with atopic dermatitis as a control subject was enriched
by immunoprecipitation and analysed by non-reduced
SDS-PAGE, which is shown in Fig. 1. There was a
clear band with molecular weight between 160 and
220 kDa in each sample, which is close to the predicted
molecular weight of IgE (190 kDa). Each band was
digested by trypsin and identified as human IgE by
proteomic MALDI-TOF/TOF analysis (Supplementary
Table 1 and Supplementary Table 2). As detailed below,
the two IgE bands were subjected to glycoproteomic
ana lys i s by on- l ine nano-LC-MS. In addi t ion
Supp lemen ta ry Tab le 8–11 compi l e the non-
glycosylated IgE peptides also characterised in this
analysis.
Glycoproteomic analysis of Asn21
Glycosylation at Asn21 of the IgE from a patient with PGM3
mutation is shown in Fig. 2. Glycopeptides generated by chy-
motryptic digestion (12TRCCKNIPSNATSVTL27) were de-
tected eluting at three time points. Glycopeptides with non-
sialylated glycans (Hex5HexNAc4-5Fuc) eluted between 30.5
and 31.5 min, those with mostly mono-sialylated glycans
(NeuAc0-1Hex5HexNAc4-5Fuc) eluted between from 32.5 to
33.5 min, and those with mostly bi-sialylated glycans
(NeuAc1-2Hex4-5HexNAc4-5Fuc) eluted between 35 and
37 min. All glycans were fucosylated and compositions
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consistent with bi-antennary structures dominated the spectra.
The glycopeptides of the IgE from a control subject revealed a
similar glycosylation profile (Table 1, Supplementary
Figure 1, Supplementary Table 3).
Glycoproteomic analysis of Asn49
Glycosylation at Asn49 of the IgE from a patient with PGM3
mutation is shown in Fig. 3 (Table 1). Glycopeptides generated
by chymotryptic digestion (44DTGSLNGTTMTLPATTL60)
were detected eluting at three time points. Glycopeptides with
non-sialylated glycans (Hex5HexNAc4-5Fuc) eluted between
37 and 38 min, those with mostly mono-sialylated glycans
(NeuAc0-1Hex4-5HexNAc4-5Fuc) eluted between from 40 to
42 min, and those with mostly bi-sialylated glycans (NeuAc1-
2Hex4-5HexNAc4-5Fuc) eluted between 46 and 47.5 min. All
glycans were fucosylated and compositions consistent with bi-
antennary structures dominated the spectra. Again the glyco-
peptides of the IgE from a control subject revealed a similar
1 2 1 2
IgE from a patient
with allergy
IgE from a patient
with PGM3 mutation
Fig. 1 SDS-PAGE of immunoprecipitated IgE. 600 ul of serum from a
patient with atopic dermatitis as a control subject and 600 ul of plasma
from a patient with hyper IgE syndrome were used to prepare IgE.
Elutions of immunoprecipitation were analyzed by non-reduced SDS-
PAGE in 3–8 % Tris-acetate gel with Tris-acetate running buffer. Lane
1: Control resin. Lane 2: Immunoprecipitated IgE. A band was observed
between 220 and 160 kDa in Lane 2, which is consistent with the
molecular weight of IgE
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Fig. 2 Glycosylation of IgE
Asn21 from a PGM3 patient.
Data were acquired by LC/MS.
The glycopeptides were produced
by chymotrypsin digestion. The
peptide backbone is presented as
a black bar under each glycan
(12TRCCKNIPSNATSVTL27).
The ions are in the form of M+
nHn+. Glycopeptides were
detected eluting at three time
points: from 30.5 to 31.5 min (a),
from 32.5 to 33.5 min (b) and
from 35 to 37 min (c). The glycan
structures were deduced
according to the molecular
weight, fragmention of
glycopeptides by MS/MS
analysis, previous glycomic
analysis of released IgE N-
glycans and knowledge of N-
glycosylation biosynthetic
pathways
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Table 1 Summary of distribution of glycan structures among the IgE glycosylation sites mapped using our glycoproteomic strategy. For detailed
description see Supplementary Tables 3–7
Site Peptide sequence Glycan structures
Protease 
used
Figures and 
Tables
Asn 21 12TRCCKNIPSNATSVTL27 Chymo
Figure 2
Supp. Figure 1
Supp. Table 3
Asn 49 44DTGSLNGTTMTLPATTL60 Chymo
Figure 3
Supp. Figure 2 
Supp. Table 4
Asn 99 87VAHTPSSTDWVDNK100 Trypsin
Figure 4
Supp. Figure 5 
Supp. Table 5
Asn 252 249GTVNLTWSR257 Trypsin
Figure 5&6
Supp. Figure 7&8
Supp. Table 6&7
Asn 275 275NGTLTVTSTLPVGTR289 Trypsin
Figure 6
Supp. Figure 7
Supp. Table 6
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glycosylation profile (Table 1, Supplementary Figure 2,
Supplementary Table 4). The N-glycosylation profiles of both
IgE samples are very similar at Asn22 and Asn49 with non-
sialylated, mono-sialylated and bi-sialylated glycopeptides.
To provide additional levels of structural definition
MS/MS analysis was performed on selected molecular
ions. Exemplary ESI-CID-MS/MS data of m/z 1066.64+
are shown in Supplementary Figure 3. The spectrum is
dominated by glycan fragment ions (m/z 168, 186, 204
derived from GlcNAc; m/z 256, 274 and 292 derived
from sialic acid and m/z 366 derived from LacNAc).
Moreover, two C-terminal peptide fragments were de-
tected at m/z 502 and 615. Collectively the data show
that m/z 1066.64+ is the chymotryptic glycopeptide
spanning Asn-49 carrying a core fucosylated, bisected,
disialylated biantennary glycan.
Glycoproteomic analysis of Asn99
A greater diversity of N-glycan structures was observed at
Asn99 compared to Asn 21 and Asn49 in the two IgE sam-
ples. As indicated in Fig. 4 (Table 1 and Supplementary
Table 5) glycopeptides generated by tryptic digestion
(87VAHTPSSTDWVDNK100) of IgE from a patient with
PGM3 mutation were detected eluting between 21 to
23 min. Compositionally the major N-glycans had bi-
antennary structures with fucose and sialic acid, for example
the two most abundant molecular ions at m/z 1206.13+ and
1303.23+. A non-fucosylated glycan at m/z 1157.43+ was de-
tected in both samples with low intensity. A small amount of
non-sialylated glycans were detected, such as the peaks atm/z
1109.13+ and m/z 1176.82+. Potential tri-antennary glycans
were observed at m/z 996.24+, m/z 1327.93+, and 1424.93+ as
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Fig. 3 Glycosylation of IgE
Asn49 from a PGM3 patient.
Data were acquired by LC/MS.
The glycopeptides were produced
by chymotrypsin digestion. The
peptide backbone
(44DTGSLNGTTMTLPATTL60)
is presented as a black bar under
each glycan. The ions are in the
form of M+nHn+. Glycopeptides
were detected eluting at three time
points: from 37 to 38 min (a),
from 40 to 42min (b) and from 46
to 47.5 min (c). The glycan
structures were deduced
according to the molecular
weight, fragmention of
glycopeptides by MS/MS
analysis, previous glycomic
analysis of released IgE N-
glycans and knowledge of N-
glycosylation biosynthetic
pathways
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well as compositions consistent with mono-antennary com-
plex structures such as m/z 1480.62+, m/z 1545.22+, and
1626.22+. ESI-CID-MS/MS of the glycopeptide at m/z
1206.13+ is shown in Supplementary Figure 4. Similar to the
fragment patterns observed in Supplementary Figure 3, glycan
fragments at lowm/z range dominated the spectra. The peptide
containing a GlcNAc residue (m/z 880.42+ and m/z 1759.9+)
and the peptide with a GlcNAc and a Fuc residue (m/z
1905.8+) provide strong evidence for the presence of core
fucosylation. In addition, peptide y ions with glycan frag-
ments were detected (m/z 982.12+, 1063.02+, 1144.02+ and
m/z 1351.6+), which provides further information on both
peptide sequence and glycan core structures. Again the glyco-
peptides of the IgE from a control subject revealed a similar
glycosylation profile (Table 1, Supplementary Figure 5).
Glycoproteomic analysis of Asn252 and Asn275
Glycosylation at Asn252 of the IgE from a patient with PGM3
mutation is shown in Figs. 5 and 6 (Table 1, Supplementary
Table 6, 7). Glycopeptides generated by tryptic digestion
(249GTVNLTWSR257) were detected eluting at two time points.
At the first time point between 27.5 and 32 min glycopeptides
containing Asn275 (275NGTLTVTSTLPVGTR289) were also
observed. Glycosylation at Asn252 (NeuAc0-1Hex4-6HexNAc4-
5Fuc1) contained mainly mono-sialylated bi-antennary glycans,
such asm/z 1099.43+ andm/z 1031.73+, except for a tri-antennary
glycan with a single sialic acid at m/z 1153.53+. ESI-CID-MS/
MS of m/z 1002.4+ of the PGM3 patient (Supplementary
Figure 6) confirmed the core fucosylated, non-sialylated glycan
structure as annotated in the MS studies (Fig. 5). The second
time point between 34.5 min and 36.5 min, contained exclusive-
ly Asn252 containing glycopeptides. Mainly bi-sialyated gly-
cans were observed (NeuAc0-2Hex3-5HexNAc3-5Fuc1), as well
as compositions consistent with mono-antennary complex struc-
tures such as m/z 1364.62+.
In contrast N-glycans at Asn275 were high mannose glycans
(Hex5-9HexNAc2) and paucimannose glycans (Hex2-
4HexNAc2) (Fig. 6, Table 1, Supplementary Table 7).
Glycopeptides of the IgE from a control subject revealed a sim-
ilar glycosylation profile (Table 1, Supplementary Figure 7, 8).
Analysis of Asn264
Glycosylation at Asn264 was not observed and the
unglycosylated tryptic peptide (258ASGKPVNHSTR268),
was detected in both IgE samples (Supplementary Figure 9,
Supplementary Figure 10) at m/z 385.23+ and m/z 577.32+.
The MS/MS of m/z 385.23+ confirmed the peptide sequence
(Supplementary figure 11).
Discussion
We previously demonstrated that the overall IgE N-glycan
profiles were similar between a patient with PGM3 mutation
and patient with atopic dermatitis as a control subject [23]. In
this paper we have now shown by glycoproteomic studies that
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the two types of IgE had similar site specific N-glycosylation.
These observations together with a recent report [14]
demonstrate that IgE glycosylation is similar among healthy
controls, allergy patients and patients with PGM3 related
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hyper IgE syndrome. Our glycoproteomic studies found that
Asn264 was not occupied by N-glycans and Asn275 had only
high mannose glycans, which is consistent with all previous
site specific glycosylation studies [10–12, 14]. A trace amount
of Fuc was detected in an myeloma IgE at Asn99 reported in
1970s [10–12], which is in contrast to the latest
glycoproteomic report [14]. Our studies again found the gly-
cans were mostly core fucosylated at this site. A HPLC based
glycomic analysis [13] of an allergic IgE indicated that all the
seven potential N-glycosylation sites were glycosylated, while
our results together with previous studies [10–12] and the
most recent report [14] showed Asn 264 is not glycosylated.
Asn146 was not mapped in this study, which coincides with a
previous report that this site cannot be mapped by trypsin or
chymotrypsin digestion [14]. Nevertheless, despite not
characterising glycosylation at Asn146 we still conclude that
IgE glycosylation does not change in allergy and PGM3 relat-
ed hyper IgE syndrome, because we have both the overall
glycan profile of IgE and glycoproteomic data from 6 of the
7 glycosylation sites in the glycoproteomic data. Combining
the two sets of data, we feel it is highly unlikely that the
glycosylation at Asn146 does change.
Both glycomic [23] and glycoproteomic studies showed
PGM3 mutation did not affect IgE glycosylation, although ele-
vated IgE is a key symptom in these patients. A possible expla-
nation is that the major complex N-glyans on IgE have bi-
antennary structures. Our previous studies of B cells and neutro-
phils from PGM3 mutation patients have shown that tri-/tetra-
antennary glycans are most sensitive to biochemical changes
caused by PGM3 mutation, while bi-antennary glycans are not
as sensitive [23]. The elevated IgE may be caused by decreased
tri-/tetra-antennary glycans on other glycoproteins that are in-
volved in IgE production. In addition, it has been known that
O-GlcNAcylation is hypersensitive to UDP-GlcNAc concentra-
tion [25]. Amouse model with hypomorphic mutations in Pgm3
has shown decreased O-GlcNAcylation [26]. Therefore, impair-
ment of O-GlcNAcylation could be another cause of the elevated
IgE in the patients.
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